Michal J.
- Country
- Poland
- Department
- Oncology
Research Overview
- Study of Inavolisib with Trastuzumab and Pertuzumab as Maintenance Therapy in Patients with HER2‑Positive PIK3CA‑Mutated Locally Advanced or Metastatic Breast Cancer
- Efficacy and Safety of Giredestrant vs. Fulvestrant with CDK4/6 Inhibitor in ER+ HER2- Advanced Breast Cancer Resistant to Endocrine Therapy
- Efficacy and Safety of Lasofoxifene and Abemaciclib vs. Fulvestrant and Abemaciclib in ER+/HER2- Advanced Breast Cancer with ESR1 Mutation
Data & Insights
Has run more than one trial at 271 of 493 partner sites.
Specializations
HER2-Positive Breast Cancer Research
The investigator specializes in studying HER2-positive breast cancer treatments, with particular focus on early-stage and metastatic disease management. Their research encompasses innovative therapeutic combinations including trastuzumab emtansine and tucatinib-based treatments.
- Advanced HER2+ breast cancer interventions
- Adjuvant therapy optimization
- Novel therapeutic combinations
Hormone Receptor-Positive Disease
Focused on advancing treatment options for HR-positive/HER2-negative breast cancer, the investigator explores novel therapeutic approaches including CDK4/6 inhibitors and innovative endocrine therapy combinations. Their work extends to both early-stage and advanced disease settings.
- Endocrine therapy resistance
- Advanced breast cancer treatments
- ESR1 mutation targeted therapies
Triple-Negative Breast Cancer
The investigator conducts research in triple-negative breast cancer treatment, investigating immunotherapy approaches and novel targeted agents. Their work includes studies of preoperative immunotherapy and innovative combination strategies.
- Immunotherapy applications
- Treatment-resistant disease
- Novel therapeutic strategies
Cardio-Oncology Research
Specialized in studying cancer treatment-related cardiotoxicity, the investigator focuses on preventive strategies during breast cancer therapy. Their research includes evaluation of cardiac protective agents during systemic cancer treatments.
- Cardioprotection strategies
- Treatment-related heart failure
- Long-term cardiac monitoring
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.